Standardized Treatment Eliminates Outcome Disparities in Non-Metastatic Osteosarcoma
Survival outcomes for patients on the EURAMOS-1 trial were not affected by race/ethnicity or poverty exposure.
Survival outcomes for patients on the EURAMOS-1 trial were not affected by race/ethnicity or poverty exposure.
Ifosfamide improved event-free and overall survival.
Twenty-three percent of adolescents and young adults with sarcoma who used opioids during treatment had new persistent opioid use after treatment.
In a phase 2 study, researchers are investigating the combination of cryoablation and dual checkpoint inhibition.
Lurbinectedin produced an overall response rate of 14.3% and a disease control rate of 57.1%.
High-dose treosulfan plus melphalan followed by autologous stem cell reinfusion did not improve event-free or overall survival.
Nearly 70% of patients had at least 1 potentially actionable therapeutic target.
This weekly series highlights eponyms in oncology. This week, we explore the history and namesakes of Li-Fraumeni syndrome.
Researchers compared carotuximab plus pazopanib with pazopanib alone in patients with advanced angiosarcoma.
In a pooled analysis of 6 studies, 44% of patients responded to combination irinotecan and temozolomide.